Frank Roger Fontaine

Title: Frank Roger Fontaine: Innovator in Angiogenesis Research

Introduction

Frank Roger Fontaine is a notable inventor based in Kenmore, Australia. He has made significant contributions to the field of medical research, particularly in the area of angiogenesis and lymphangiogenesis. With a total of 2 patents, Fontaine's work focuses on innovative methods for treating diseases related to these processes.

Latest Patents

Fontaine's latest patents include groundbreaking compounds and methods aimed at inhibiting SOX18 protein activity. The first patent discloses compounds that demonstrate efficacy in inhibiting SOX18's ability to bind DNA and specific protein partners. This research is particularly relevant for developing treatments for angiogenesis- and lymphangiogenesis-related diseases, such as cancer metastasis and vascular cancers. The second patent further elaborates on inhibitors of SOX18 protein activity, reinforcing the potential for these compounds in therapeutic applications.

Career Highlights

Frank Roger Fontaine is affiliated with the University of Queensland, where he conducts his research. His work has garnered attention for its potential impact on treating serious medical conditions. Fontaine's innovative approach to understanding the role of SOX18 in disease progression has positioned him as a key figure in his field.

Collaborations

Fontaine collaborates with esteemed colleagues, including Mathias Francois and Johannes Zuegg. These partnerships enhance the research efforts and contribute to the advancement of knowledge in the field of angiogenesis.

Conclusion

Frank Roger Fontaine's contributions to medical research through his patents and collaborations highlight his commitment to innovation in treating complex diseases. His work continues to pave the way for new therapeutic strategies in the fight against cancer and related disorders.